Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tennessee
Clinical trial register · United States · industry-sponsored

Clinical Trials in Tennessee, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca27 Novartis Pharmaceuticals16 Hoffmann-La Roche15 Merck Sharp & Dohme LLC14 AbbVie12
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Tennessee

670 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
IKS04 Regimen in Advanced Solid Tumors That Express CA242
NCT07738939Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
Iksuda Therapeutics Ltd.
Phase 1
120
California, Massachusetts, Tennessee, Texas
2026-11
Not yet open
A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer
NCT07851103Advanced Solid Tumour
DrugEzabenlimab
Boehringer Ingelheim
Phase 1
90
Florida, Georgia, Pennsylvania, Tennessee, Texas
2026-10-26
Not yet open
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649Endometrial Neoplasms, Endometrial Cancer
DrugsPF-08634404·Keytruda·Pembrolizumab
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Not yet open
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
DrugsObrixtamig·Pumitamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 1/2
55
Florida, Massachusetts, New Jersey, New York, Tennessee
2026-10-05
Not yet open
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
NCT07083765Hypertension, Hypertension,Essential
DrugAlcohol
Ablative Solutions, Inc.
Phase 3
202
Tennessee
2026-10
Not yet open
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
NCT07526974Subcutaneous Fat
DrugCBL-514
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Georgia, Maryland, Nebraska, New York, Ohio, Tennessee
2026-10
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
California, Florida, Illinois, Maryland, Massachusetts, New York, Ohio, Tennessee
2026-09-30
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
California, Florida, New Jersey, Tennessee, Utah
2026-09-24
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
DrugsPatritumab deruxtecan·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
Recruiting
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
NCT07828860Hidradenitis Suppurativa (HS)
DrugSoquelitinib
Corvus Pharmaceuticals, Inc.
Phase 1
25
Indiana, Kentucky, Massachusetts, New York, North Dakota, Ohio, Pennsylvania, Tennessee
2026-09-17
Recruiting
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
NCT07832292Prostatic Neoplasms
DrugJNJ-101556143
Janssen Research & Development, LLC
Phase 2
100
Louisiana, Massachusetts, New York, Tennessee
2026-09-16
Recruiting
Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
NCT07788521Visual Acuity
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Evaluation of Approved Contact Lenses (CR-6657)
NCT07819305Visual Acuity
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Illinois, New York, Ohio, Tennessee, Texas, Virginia
2026-09-10
Recruiting
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
NCT07815665Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
DrugsEnfortumab Vedotin·Pembrolizumab
Summit Therapeutics
Phase 2/3
800
Arizona, California, District of Columbia, Florida, Minnesota, Tennessee, Washington
2026-09-10
Recruiting
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
NCT07813637Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
DrugJANX007
Janux Therapeutics
Phase 1
110
Tennessee
2026-09-10
Recruiting
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
NCT07609719Multiple Sclerosis
Genentech, Inc.
Phase 4
100
Arizona, Florida, Georgia, Tennessee
2026-09-02
Not yet open
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
Abiomed Inc.
Not applicable
250
Florida, Indiana, Minnesota, Missouri, New Jersey, North Carolina, Pennsylvania, Tennessee
2026-09-01
Not yet open
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
NCT06432166Alzheimer Disease, Mild Cognitive Impairment
MTI Biotech Inc
Phase 1/2
48
Tennessee
2026-09-01
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
NCT07594119Focal Seizure, Epilepsy, Focal Epilepsy
DrugRAP-219
Rapport Therapeutics Inc.
Phase 3
312
Alabama, Arkansas, Colorado, Florida, Illinois, New York, North Carolina, Tennessee
2026-09
Recruiting
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
NCT07794670Preclinical Alzheimer's Disease
DrugObicetrapib
NewAmsterdam Pharma
Phase 2
400
Tennessee
2026-09
Recruiting
JUR-003 in Adult Patients With Metastatic Prostate Cancer
NCT07824349Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
Juri Biosciences, Inc.
Phase 1
210
Michigan, New York, Tennessee
2026-09
Not yet open
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
NCT06534502Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial
Azurity Pharmaceuticals
Phase 4
40
North Carolina, Tennessee
2026-09
Not yet open
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
DrugSI-B036
SystImmune Inc.
Phase 1
424
Connecticut, Florida, Oklahoma, Tennessee, Texas
2026-09
Recruiting
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
NCT07686081Ulcerative Colitis (UC)
DrugPonesimod
Vanda Pharmaceuticals
Phase 3
150
California, Tennessee
2026-09
Not yet open
Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).
NCT07838506Neuropathic Corneal Pain
Okyo Pharma Ltd
Phase 3
111
Tennessee
2026-09
By invitation
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
NCT07775976Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
Peerbridge Health, Inc
Observational
1,000
California, Tennessee
2026-08-20
Recruiting
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
NCT07756580Glabellar Lines
DrugsAGN-151586·Botox
AbbVie
Phase 1
120
Arizona, California, Louisiana, Massachusetts, North Carolina, Tennessee, Texas
2026-08-10
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
New Jersey, Ohio, Oklahoma, Tennessee
2026-08-06
By invitation
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
NCT07773883ADHD
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
300
Alabama, Florida, Tennessee
2026-08-06
Recruiting
Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation
NCT07335523Exocrine Pancreatic Insuficiency
Digestive Care, Inc.
Observational
30
Colorado, New York, Ohio, Oregon, Tennessee, Texas, Washington
2026-08-03
Recruiting
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248Metastatic Castration Resistant Prostate Cancer
DrugsRinzimetostat·Xtandi·Taxotere·Darolutamide
ORIC Pharmaceuticals
Phase 3
600
Florida, Indiana, Michigan, North Carolina, Ohio, South Carolina, Tennessee, Texas
2026-08-03
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
Cryoablation for Monomorphic Ventricular Tachycardia (VTS)
NCT07650032Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic
Adagio Medical
Not applicable
100
Arizona, California, Massachusetts, New York, Pennsylvania, South Carolina, Tennessee, Virginia
2026-08-01
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Obinutuzumab·Venetoclax·Rituximab
Nurix Therapeutics, Inc.
Phase 1/2
150
Colorado, Florida, Oregon, Pennsylvania, Tennessee, Texas
2026-08
Not yet open
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
NCT07707674Metastatic Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1
24
Michigan, New York, Ohio, Oklahoma, Tennessee, Texas
2026-07-30
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795Colorectal Cancer
DrugsVS-7375·Panitumumab·MFOLFOX6·Cetuximab
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, Tennessee
2026-07-28
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596Relapsed or Refractory Multiple Myeloma
DrugsAldesleukin·Daratumumab
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
NCT07585266Gastrointestinal Stromal Neoplasms
DrugsVelzatinib·Imatinib
GlaxoSmithKline
Phase 3
800
Arizona, California, Connecticut, Maryland, Nebraska, New York, Ohio, Tennessee
2026-07-27
Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT07755436Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
ArriVent BioPharma, Inc.
Phase 1
180
Florida, Massachusetts, Tennessee, Texas, Virginia
2026-07-23
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
NCT07635563Obstructive Sleep Apnea (OSA)
DrugAcetazolamide
Incannex Healthcare Ltd
Phase 2
120
California, Florida, Louisiana, Maryland, Ohio, South Carolina, Tennessee, Texas
2026-07-21
Recruiting
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
NCT07629206Low-Risk, Early Stage Breast Cancer
IceCure Medical Ltd.
Not applicable
400
California, Tennessee
2026-07-17
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
NCT07652242Triple Negative Breast Cancer (TNBC)
DrugsOlaparib·Capecitabine·Pembrolizumab
Immunomic Therapeutics, Inc.
Phase 1
60
Michigan, Tennessee
2026-07-14
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
DrugEmpasiprubart
argenx
Phase 2
40
Florida, New York, Tennessee, Texas
2026-07-10
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
California, Florida, Illinois, Massachusetts, Oregon, Tennessee
2026-07-08
Recruiting
Axonics R20 Post-Market Clinical Follow-up (PMCF) Study for the Indication of Fecal Incontinence
NCT07499258Fecal Incontinence
Axonics, Inc.
Observational
55
New York, Tennessee, Texas
2026-07-02
Recruiting
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
NCT07426757Advanced Malignancies, Advanced Cancer
DrugMidazolam
Pfizer
Phase 1
120
Colorado, Florida, Georgia, Tennessee
2026-07-01
Not yet open
KPAP Adherence Crossover Study
NCT06413134Obstructive Sleep Apnea
SleepRes Inc.
Not applicable
30
Tennessee
2026-07-01
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
NCT07489066Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Nebraska, New Mexico, Tennessee
2026-06-30
Recruiting
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT07751042Advanced Solid Tumor
DrugKeytruda
Strand Therapeutics Inc.
Phase 1/2
220
Arizona, Massachusetts, Tennessee
2026-06-30
Recruiting
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
NCT07749170Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Penumbra Inc.
Observational
250
Tennessee
2026-06-26
Recruiting
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602Idiopathic Pulmonary Fibrosis (IPF)
DrugsDeupirfenidone·Pirfenidone
PureTech
Phase 3
1,100
California, Massachusetts, Nevada, Pennsylvania, South Carolina, Tennessee, Texas
2026-06-26
Recruiting
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Kardigan, Inc.
Phase 2
140
Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee
2026-06-23
Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Moonlight Bio, Inc
Phase 1
110
Missouri, New Jersey, New York, Tennessee, Texas
2026-06-23
Recruiting
A Study of MZE782 in Adults With PKU
NCT07694440Phenylketonuria (PKU)
Maze Therapeutics
Phase 2
38
California, Indiana, Kentucky, Pennsylvania, Tennessee
2026-06-23
Recruiting
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471Follicular Lymphoma
DrugsRituximab Biosimilar·MK-1045·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 2/3
960
California, Kentucky, New Jersey, North Carolina, Tennessee
2026-06-22
Recruiting
ColoSeal™ ICD System Anastomotic Protection Pivotal Study
NCT07429110Rectal Cancer Surgery
Averto Medical, Inc.
Not applicable
250
Florida, Ohio, South Carolina, Tennessee, Utah
2026-06-19
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
DrugsEIK1001·Cisplatin/Carboplatin·Nab-paclitaxel·Pemetrexed
Eikon Therapeutics
Phase 2/3
750
Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee
2026-06-15
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Active, closed
Collection of Training Data for LuminX Probe AI Models
NCT07565480Data Collection for AI Training of Dental Prob
LuminX
Not applicable
150
California, Florida, Tennessee
2026-06-03
Recruiting
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
NCT07566286Chin Augmentation
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Not yet open
A Study of CS231295 in Patients With Advanced Solid Tumors
NCT07612488Advance Solid Tumors, Advanced Malignant Solid Tumors
ThalassaX Therapeutics United States Ltd
Phase 1
42
Colorado, Florida, Massachusetts, Tennessee
2026-06
Not yet open
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
NCT07676097Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
AngioInsight
Observational
620
California, District of Columbia, Minnesota, New Jersey, New York, Ohio, Tennessee
2026-06
Recruiting
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 1
114
California, Florida, North Carolina, South Carolina, Tennessee, Texas
2026-05-29
Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07607964Systemic Lupus Erythematosus, Rheumatoid Arthritis
AbbVie
Phase 1
30
Alabama, California, Florida, Illinois, Tennessee, Texas
2026-05-28
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Compass Therapeutics
Phase 1
70
Arizona, Florida, Minnesota, Nebraska, New York, Pennsylvania, South Carolina, Tennessee
2026-05-28
Recruiting
Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency
NCT07636590Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine
Hoffmann-La Roche
Phase 2/3
650
New Jersey, New York, Tennessee
2026-05-21
Recruiting
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
NCT07531745Dravet Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
32
Michigan, Minnesota, North Carolina, Tennessee, Washington
2026-05-21
Recruiting
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832Acute Myeloid Leukemia
DrugPivekimab Sunirine
AbbVie
Phase 1
18
California, Georgia, New York, Tennessee, Texas
2026-05-20
Recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
NCT07646613Migraine
Aspeya, Inc.
Phase 2
108
California, Florida, Nevada, Tennessee, Utah
2026-05-19
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Arizona, California, Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-05-17
Recruiting
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670Alzheimer's Disease
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
NCT06930755Ovarian Cancer
DrugsNMS-03305293·Topotecan
Nerviano Medical Sciences
Phase 1
24
Illinois, Missouri, Pennsylvania, Tennessee, Texas
2026-05-13
Recruiting
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702Myasthenia Gravis, Generalized
DrugPovetacicept
Vertex Pharmaceuticals Incorporated
Phase 2
30
California, Florida, Hawaii, Illinois, Nevada, South Carolina, Tennessee, Texas
2026-05-13
Recruiting
A Study of TAK-505 in Adults With Solid Tumors
NCT07436728Malignant Solid Tumors
Takeda
Phase 1/2
151
California, Florida, Minnesota, New York, Ohio, Tennessee, Texas, Virginia
2026-05-11
Recruiting
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
NCT07610837Liver Fibrosis, Hepatic Cirrhosis
AstraZeneca
Phase 2
104
Arizona, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma, Tennessee
2026-05-07
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Bevacizumab
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York, Tennessee
2026-05-06
Recruiting
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
NCT07427394Advanced Breast Cancer
DrugsAtirmociclib·Camizestrant
AstraZeneca
Phase 2
24
Missouri, Rhode Island, Tennessee
2026-05-06
Active, closed
Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study
NCT07425587Sepsis, Septic Shock
Bluejay Diagnostics, Inc.
Observational
450
Florida, Massachusetts, North Carolina, Tennessee, Utah
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Colorado, Tennessee
2026-05-03
Recruiting
Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection
NCT07435649Central Nervous System Infection
Delve Bio, Inc.
Not applicable
400
California, Georgia, Maryland, Massachusetts, Tennessee
2026-05-01
Recruiting
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
NCT07607678Advanced Solid Cancer, Metastatic Solid Cancer
DrugEzabenlimab
Boehringer Ingelheim
Phase 1
60
Connecticut, New Jersey, New York, Tennessee
2026-05-01
Recruiting
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
NCT07563829Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc.
Phase 1
81
California, Maryland, New York, Tennessee, Texas, Virginia
2026-05-01
Recruiting
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
NCT07348601Prader-Willi Syndrome
ConSynance Therapeutics
Phase 2
12
Tennessee
2026-05
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
Prelude Therapeutics Incorporated
Phase 1
100
California, Colorado, Florida, Michigan, Pennsylvania, Tennessee, Texas
2026-04-29
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
NCT07567846Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1/2
260
Arizona, Tennessee
2026-04-29
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugXaluritamig
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
CVRx, Inc.
Not applicable
2,500
Alabama, Florida, Missouri, Nebraska, Ohio, South Dakota, Tennessee, Texas
2026-04-24
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
DrugsBNT324·Prednisone/Prednisolone·Docetaxel
BioNTech SE
Phase 3
736
California, Colorado, Florida, Illinois, Maryland, New York, Ohio, Tennessee
2026-04-22
Recruiting
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
NCT07612189Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
Florida, New York, Tennessee, Texas, Virginia
2026-04-22
Recruiting
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT07558733HR+ HER2- Breast Cancer
DrugsSerabelisib·Sapanisertib·Fulvestrant
Faeth Therapeutics
Phase 1/2
32
California, Colorado, Oregon, Tennessee, Texas
2026-04-22
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522Diabetic Macular Edema
DrugFaricimab
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095Small Cell Lung Cancer
DrugsZL-1310·Tarlatamab·Durvalumab
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
NCT07612176Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
New York, Tennessee, Texas, Virginia
2026-04-21
Recruiting
EEG Abnormalities in Adult ICU Patients With High Risk of Delirium
NCT07485244Delirium in the Intensive Care Unit
Ceribell Inc.
Observational
100
Tennessee
2026-04-16
Recruiting
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
NCT07548632Dry Eye Disease (DED)
Oculis
Phase 2/3
160
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Virginia
2026-04-16
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Janux Therapeutics
Phase 1
43
California, Missouri, South Carolina, Tennessee, Texas
2026-04-15
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Connecticut, New York, South Carolina, Tennessee, Texas
2026-04-14
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Florida, Massachusetts, Ohio, Tennessee, Utah
2026-04-13
Recruiting
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07533175Diabetes Mellitus, Overweight, Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
630
Alabama, California, Florida, Minnesota, New York, South Carolina, Tennessee, Texas
2026-04-13
Recruiting
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
NCT07175441Advanced Unresectable Hepatocellular Carcinoma
DrugsSTRIDE (durvalumab·RBS2418·Tremelimumab
Riboscience, LLC.
Phase 2
220
Maryland, Tennessee, Texas
2026-04-10
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495Carcinoma, Renal Cell
DrugsZanzalintinib·Belzutifan
Merck Sharp & Dohme LLC
Phase 3
758
Georgia, Missouri, New York, Tennessee
2026-04-09
Recruiting
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
NCT07524855Metastatic Breast Cancer
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
California, Illinois, Indiana, Maine, Tennessee, Texas
2026-04-08
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Colorado, Connecticut, Tennessee, Virginia
2026-04-08
Not yet open
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
NCT07513506Growth
Mead Johnson Nutrition
Not applicable
214
Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas
2026-04-03
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT07540221CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugsGamunex-C·Xembify
Grifols Therapeutics LLC
Phase 3
40
California, Florida, New York, Tennessee, Texas
2026-04-02
Not yet open
Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)
NCT07412626Congestive Heart Failure Chronic, Low Ejection Fraction
Robert Pickett
Not applicable
135
Indiana, Tennessee
2026-04-01
Recruiting
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
NCT07439653Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC
Phase 1/2
155
California, Florida, Iowa, Kansas, Tennessee, Texas
2026-03-31
Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NCT07462377Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell
EpiBiologics
Phase 1
110
California, New Jersey, New York, Tennessee, Texas
2026-03-31
Not yet open
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
NCT03606538Pharmacokinetics, Hepatic Impairment
DrugsMidomafetamine HCl·MDMA
Resilient Pharmaceuticals
Phase 1
16
Tennessee
2026-03-29
By invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
NCT07338968Choroidal Melanoma, Indeterminate Lesions
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab
Merck Sharp & Dohme LLC
Phase 3
450
Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Washington
2026-03-23
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Massachusetts, Tennessee, Texas, Utah
2026-03-19
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Yervoy·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Ohio, Tennessee, Texas
2026-03-11
Active, closed
Endometrial Cancer Vaginal Fluid Specimen Collection Study
NCT07544680Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
Exact Sciences Corporation
Observational
4,200
Florida, Maine, Tennessee, Texas
2026-03-10
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1
35
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07221838Generalized Myasthenia Gravis, gMG
DrugsPrednisone/Prednisolone·Ravulizumab
Alexion Pharmaceuticals, Inc.
Phase 4
75
Illinois, New Jersey, North Carolina, Tennessee
2026-03-04
Not yet open
Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
NCT03176186Post-Cardiac Arrest Syndrome
Invero Pharma, Inc.
Phase 3
1,436
Connecticut, Florida, Mississippi, Nebraska, New York, Ohio, Tennessee, Texas
2026-03
Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425Solid Tumours, Melanoma
Boehringer Ingelheim
Phase 1
69
Kentucky, Tennessee, Texas, Virginia
2026-02-24
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
NCT06875960Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 4
35
Connecticut, New York, Oklahoma, Tennessee
2026-02-24
Recruiting
A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.
NCT05361733Focus of the Study: Safety of XFB19
Xfibra, Inc.
Phase 1
40
Tennessee
2026-02-17
Recruiting
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
NCT07197944Short Bowel Syndrome
DrugGlepaglutide
Zealand Pharma
Phase 3
90
Illinois, Missouri, Nebraska, New York, Pennsylvania, Tennessee
2026-02-11
Recruiting
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury
NCT07455136Traumatic Brain Injury
Hoffmann-La Roche
Observational
2,000
California, Indiana, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee
2026-02-09
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen
Phase 1/2
102
Michigan, Tennessee, Texas
2026-02-06
Recruiting
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995Locally Advanced or Metastatic Malignant Solid Tumors
DrugsEnfortumab Vedotin·Keytruda·Carboplatin·Pembrolizumab
Astellas Pharma Global Development, Inc.
Phase 1/2
428
New Jersey, New York, Tennessee, Virginia
2026-02-05
Recruiting
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
NCT07372625TP53 Y220C Mutation, Advanced Solid Tumors
DrugsRezatapopt·Repaglinide·Midazolam Hydrochloride·Metformin Hydrochloride
PMV Pharmaceuticals, Inc
Phase 1
14
Colorado, Florida, Tennessee, Texas
2026-02-04
Recruiting
A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults
NCT07370584Safety Study
iVeena Delivery Systems, Inc.
Phase 1
36
Tennessee
2026-02-04
Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07325136Relapsed/Refractory Small Cell Lung Cancer
DrugPumitamig
Bristol-Myers Squibb
Phase 1/2
240
Michigan, New York, North Carolina, Ohio, Tennessee
2026-02-03
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
DrugsNucresiran·Vutrisiran
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Recruiting
Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform
NCT07333547High-risk Cardiac Patients
Idoven 1903 S.L.
Observational
200,000
Tennessee
2026-02-03
Not yet open
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
NCT07315984Huntington Disease
BioSensics
Observational
75
New York, Tennessee
2026-01-31
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
DrugsElironrasib·Zoldonrasib·Ivonescimab·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New York, Ohio, Tennessee
2026-01-29
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
LTZ Therapeutics, Inc.
Phase 1
42
California, Missouri, New York, Tennessee, Washington
2026-01-29
Active, closed
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT07336446Prostate Cancer
DrugSaruparib
AstraZeneca
Phase 1/2
6
California, Tennessee
2026-01-27
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07195682Renal Cell Carcinoma
DrugsPumitamig·Yervoy·Ipilimumab
Bristol-Myers Squibb
Phase 1
281
Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-01-15
Recruiting
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
NCT05723926Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
Javelin Medical
Not applicable
2,000
Illinois, Massachusetts, New York, Tennessee
2026-01-09
Recruiting
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916Solid Tumors, Hematologic Malignancies
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Active, closed
Nicotine Pouch Pharmacokinetics Abuse Liability
NCT07476144Smoking Behaviors
JT International SA
Phase 1
55
Tennessee, Texas
2026-01-08
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Phase 1/2
178
Illinois, Rhode Island, Tennessee, Texas
2026-01-06
Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 2
120
California, Colorado, District of Columbia, Illinois, Minnesota, Nebraska, New York, Tennessee
2025-12-29
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Georgia, Tennessee, Texas
2025-12-29
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07246590Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Florida, Indiana, Maryland, Tennessee, Texas
2025-12-17
Recruiting
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
DrugRAP-219
Rapport Therapeutics Inc.
Phase 2
30
Idaho, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-12-15
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474Squamous Non-small Cell Lung Cancer
DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
DrugGlepaglutide
Zealand Pharma
Phase 3
28
Minnesota, Nebraska, Ohio, Tennessee
2025-12-11
Recruiting
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784Social Anxiety Disorder (SAD)
Newleos Therapeutics, Inc.
Phase 2
100
California, Florida, Massachusetts, Nevada, New York, Tennessee, Texas
2025-12-09
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
80
California, Florida, New Jersey, New York, Oregon, Tennessee
2025-12-09
Active, closed
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
NCT07134088Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 1/2
104
California, Pennsylvania, Tennessee, Washington
2025-12-08
Active, closed
A Study to Evaluate AI-09 In Participants With Glabellar Lines
NCT07321834Glabellar Lines
Eirion Therapeutics Inc.
Phase 2
68
Florida, Louisiana, Tennessee, Texas
2025-12-03
Recruiting
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
NCT07277270Neoplasms
DrugsGSK5764227·Enzalutamide·Fluorouracil·Leucovorin
GlaxoSmithKline
Phase 1
83
Florida, New York, Pennsylvania, Tennessee, Texas
2025-12-03
Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Active, closed
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
NCT07205900Obese, Obesity
DrugHM15275
Hanmi Pharmaceutical Company Limited
Phase 2
267
California, Illinois, Iowa, North Carolina, South Carolina, Tennessee, Texas
2025-12-02
Recruiting
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
NCT07395232Atopic Keratoconjunctivitis
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Active, closed
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
58
Alabama, California, Missouri, Ohio, South Carolina, Tennessee, Texas
2025-12-01
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644Solid Tumors Harboring MET Amplification
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Active, closed
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
24
Tennessee
2025-11-28
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.
NCT07225751Ankle Arthrodesis or Arthroplasty, Hindfoot Fusion, Ankle Deformity, Ankle Disease
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
DrugsYervoy·Opdivo
Shanghai Henlius Biotech
Phase 1
246
California, Florida, Tennessee, Texas, Washington
2025-11-25
Recruiting
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
Novelwise Pharmaceutical Corporation
Phase 1/2
36
Arizona, Colorado, Tennessee
2025-11-20
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
DrugPembrolizumab
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
NCT07223138Arthritis, Psoriatic
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
1,560
Arizona, Arkansas, California, Florida, North Carolina, Ohio, Pennsylvania, Tennessee
2025-11-13
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Recruiting
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
83
California, Florida, Illinois, Iowa, Tennessee, Texas
2025-11-12
Recruiting
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
NCT06798298Long Term Safety Following GM T Cell Therapy
Regeneron Pharmaceuticals
Observational
50
Tennessee
2025-11-10
By invitation
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
NCT07156578Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Colorado, Iowa, Massachusetts, New York, North Carolina, Tennessee
2025-11-10
Recruiting
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
NCT06699121Primary Sclerosing Cholangitis (PSC)
LISCure Biosciences
Phase 2
87
California, Colorado, Iowa, Maryland, Minnesota, Tennessee, Washington
2025-11
Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
NCT06934967Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
12
Georgia, New Jersey, Pennsylvania, Tennessee
2025-10-28
Active, closed
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
NCT07199569Monkeypox (Mpox)
DrugJynneos
Bavarian Nordic
Phase 2
970
Iowa, Kansas, New York, North Carolina, South Carolina, Tennessee, Texas, Virginia
2025-10-27
Recruiting
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT06992258Colorectal Cancer
DrugsLonsurf·Fruquintinib
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
Active, closed
HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU
NCT07223515Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Dynamic Medical Services dba Acesso Biologics
Observational
2,000
Michigan, Tennessee
2025-10-24
Recruiting
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
NCT07220408Allergic Conjunctivitis
DrugTL-925
Telios Pharma, Inc.
Phase 2
60
Tennessee
2025-10-23
Recruiting
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731Phenylketonuria
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
California, Florida, Illinois, Oregon, Pennsylvania, Tennessee, Texas, Utah
2025-10-20
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609Neoplasms, Colorectal, Neoplasms
GlaxoSmithKline
Phase 1/2
47
Colorado, Michigan, Ohio, Tennessee
2025-10-20
Recruiting
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
NCT07229430Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
CLASSYS Inc.
Not applicable
273
California, North Carolina, Tennessee, Washington
2025-10-16
Recruiting
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963NMIBC
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
DrugsDurvalumab·Carboplatin
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
By invitation
Novel On-body Evaluation of Cardiac Health for Oncology
NCT07158450Cardiotoxicity, Heart Failure
Skribe Medical
Observational
1,000
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Virginia
2025-10-09
Recruiting
A Study of CTD402 in T-ALL/LBL Patients
NCT07070219Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Imviva Bio
Phase 1/2
118
California, Colorado, Illinois, Minnesota, New York, Tennessee, Texas
2025-10-07
Recruiting
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT07140900Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
DrugsXaluritamig·Abiraterone·Darolutamide
Amgen
Phase 1
60
California, Massachusetts, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2025-10-07
Recruiting
Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants
NCT06613568End Stage Kidney Disease
Diality Inc.
Not applicable
50
California, New York, Tennessee, Texas, Washington
2025-10-06
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099Sjögren, Sjogren Disease, Sjogren's Syndrome
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
36
Florida, New York, Tennessee, Texas, Utah
2025-10-01
Recruiting
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
NCT07179055Dry Eye
Vanda Pharmaceuticals
Phase 2
160
California, Massachusetts, North Carolina, Tennessee, Virginia
2025-10
Recruiting
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
DrugsCetuximab·Pembrolizumab
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
California, Florida, Minnesota, New York, Ohio, South Carolina, Tennessee
2025-09-24
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
DrugsAdrucil·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Alabama, California, Colorado, District of Columbia, Florida, Louisiana, Pennsylvania, Tennessee
2025-09-16
By invitation
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
NCT07480343Open-angle Glaucoma (OAG)
Iantrek, Inc.
Observational
250
California, Florida, Georgia, Maryland, Nevada, Pennsylvania, Tennessee, Utah
2025-09-15
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07054190Breast Cancer
DrugsGiredestrant·Inavolisib·Ribociclib·Letrozole
Hoffmann-La Roche
Phase 2
120
California, Tennessee, West Virginia
2025-09-09
Recruiting
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
NCT07060716Kidney Transplant Rejection, Cell-free DNA
Insight Molecular Diagnostics
Observational
125
California, Florida, Ohio, Pennsylvania, Tennessee, Texas, Utah
2025-09-08
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707Obesity
MBX Biosciences
Phase 1
124
Florida, Kentucky, Missouri, Tennessee
2025-09-03
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
NCT06977724Dry Eye Syndrome, Systemic Lupus Erythematosus
DrugABBV-319
AbbVie
Phase 1
36
Florida, Illinois, Tennessee, Texas
2025-08-26
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Florida, Tennessee, Texas
2025-08-25
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
Recruiting
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT06998407HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
DrugsAVZO-021·Letrozole·Fulvestrant
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
By invitation
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
NCT06867107Duchenne Muscular Dystrophy (DMD)
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
30
California, Ohio, Tennessee
2025-08-20
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Recruiting
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
NCT06931626Small Cell Lung Cancer
DrugsNMS-03305293·Temozolomide
Nerviano Medical Sciences
Phase 1
10
Illinois, Massachusetts, Tennessee
2025-08-15
Recruiting
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
NCT07019922Epileptic Encephalopathy, SCN2A Encephalopathy
Praxis Precision Medicines
Phase 3
40
California, Colorado, Illinois, Ohio, Pennsylvania, Tennessee
2025-08-13
Active, closed
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
NCT07055451HIV-1-infection
DrugB/F/TAF
Gilead Sciences
Phase 1
16
California, Georgia, Tennessee
2025-08-12
Recruiting
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
NCT07122986Healthy Participants
Pfizer
Phase 1
310
California, Florida, New York, Ohio, Tennessee
2025-08-11
Recruiting
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
NCT05337241Refractory Ventricular Tachycardia
Thermedical, Inc.
Not applicable
130
Alabama, Pennsylvania, South Carolina, Tennessee, Utah
2025-08-09
Recruiting
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
NCT07021898Metastatic Solid Tumors
Erasca, Inc.
Phase 1
200
Tennessee, Texas, Washington
2025-08-06
Recruiting
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
NCT06398418Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer
Rise Therapeutics LLC
Phase 1
33
Colorado, Tennessee
2025-08-01
Not yet open
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031Bloodstream Infection, Sepsis, Septic Shock
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2025-08
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
DrugsPanitumumab·Pembrolizumab
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Recruiting
WRAP North America
NCT06807099Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
250
Alabama, Arizona, California, Florida, Kentucky, Rhode Island, South Carolina, Tennessee
2025-07-31
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
DrugBL-M05D1
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Recruiting
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905Hemophilia B
CSL Behring
Phase 3
20
California, Florida, Georgia, Michigan, Tennessee
2025-07-28
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Active, closed
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT06817382Duchenne Muscular Dystrophy
Insmed Gene Therapy LLC
Phase 1
12
Arkansas, California, Georgia, New York, Ohio, Tennessee, Virginia
2025-07-22
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan
Merck Sharp & Dohme LLC
Phase 1/2
140
California, New York, North Carolina, Pennsylvania, Tennessee
2025-07-20
Recruiting
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
NCT07015697Recurrent or Metastatic Solid Tumors
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 1
76
California, Georgia, Nevada, North Carolina, Ohio, Tennessee
2025-07-17
Recruiting
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT06994676High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Crossbow Therapeutics, Inc.
Phase 1
72
California, Florida, Illinois, Massachusetts, Missouri, New York, Pennsylvania, Tennessee
2025-07-16
Recruiting
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
NCT07107230Advanced Stage Solid Tumors
DrugAmivantamab
Janssen Research & Development, LLC
Phase 1
400
Florida, New York, Tennessee, Virginia
2025-07-15
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070Heart Transplant, Heart Failure, Transplant; Failure, Heart
XVIVO Perfusion
Not applicable
60
California, Georgia, Illinois, Missouri, Nebraska, New York, North Carolina, Tennessee
2025-07-10
Recruiting
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT06915025Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsIMNN-001·Niraparib·Olaparib·Paclitaxel
Imunon
Phase 3
500
Florida, Louisiana, Minnesota, Missouri, Oregon, South Dakota, Tennessee, Washington
2025-07-09
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide
Merck Sharp & Dohme LLC
Phase 1/2
360
California, District of Columbia, Michigan, New York, Pennsylvania, Tennessee, Washington
2025-07-03
Not yet open
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
NCT06470373Neovascular Age-related Macular Degeneration (nAMD)
DrugEylea
Rophibio, Inc.
Phase 3
434
Arizona, Arkansas, Pennsylvania, Tennessee, Texas
2025-07
Active, closed
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531Primary Sjögren's Syndrome
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
180
California, Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee
2025-06-30
Recruiting
Data Gathering for A10900
NCT07149740Retinal Disease, Healthy, Glaucoma, Corneal Diseases
Optos, PLC
Observational
180
California, Connecticut, Massachusetts, Tennessee
2025-06-26
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Erbitux·Cetuximab·Nab-paclitaxel
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
DrugZeprumetostat
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880Neoplasms, Prostate
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Active, closed
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
NCT06953583Friedreich Ataxia
DrugsOmaveloxolone·Skyclarys
Biogen
Phase 3
255
California, Florida, Pennsylvania, Tennessee, Virginia, Washington
2025-06-09
Recruiting
Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)
NCT06983041Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Coologics, Inc
Not applicable
55
Florida, Georgia, Idaho, Illinois, North Carolina, Tennessee, Texas
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Recruiting
A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)
NCT06968741Stress Urinary Incontinence (SUI)
UroMems SAS
Not applicable
140
California, Minnesota, North Carolina, Ohio, Tennessee, Texas, Virginia
2025-05-19
Recruiting
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808Perianal Fistula Due to Crohn's Disease
DrugDB-3Q
Direct Biologics, LLC
Phase 2
36
Colorado, Missouri, New York, Pennsylvania, Tennessee
2025-05-19
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281Solid Tumors
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
Auron Therapeutics, Inc.
Phase 1
69
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2025-05-01
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920Triple Negative Breast Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Colorado, Connecticut, Indiana, Tennessee, Texas
2025-04-25
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Recruiting
MMA Embolization for Refractory Chronic Migraine
NCT06735833Migraine Disorders
Cerenovus, Part of DePuy Synthes Products, Inc.
Not applicable
70
California, Connecticut, New York, Pennsylvania, Tennessee, West Virginia
2025-04-23
Recruiting
Pivotal Study for the Cardiac Performance System (CPS)
NCT06870591Cardiovascular Diseases
Sensydia Corporation
Observational
1,000
Alabama, Illinois, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Tennessee
2025-04-22
Recruiting
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038Alagille Syndrome
Ipsen
Observational
30
California, Missouri, New York, Tennessee, Texas, Utah
2025-04-22
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
NCT06858813Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
DrugLenvatinib
AbbVie
Phase 1
232
California, Illinois, Missouri, New York, Pennsylvania, Tennessee
2025-04-14
Active, closed
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NCT06903065MASH
DrugAfimkibart
Hoffmann-La Roche
Phase 1
50
Arizona, Georgia, Louisiana, Nevada, Tennessee, Texas
2025-04-14
By invitation
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
NCT06848088Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
48
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105Psoriatic Arthritis
DrugsLutikizumab·Risankizumab
AbbVie
Phase 2
120
California, Florida, Illinois, Maryland, Ohio, Pennsylvania, Tennessee, Texas
2025-04-11
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165ALS
Amylyx Pharmaceuticals Inc.
Phase 1
48
California, District of Columbia, Florida, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2025-04-07
Active, closed
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
NCT06825858Age-Related Macular Degeneration
DrugKH658
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
9
Arizona, Illinois, Tennessee
2025-04-07
Recruiting
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
NCT06834282AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
DrugsMesna·Fludarabine·Cyclophosphamide
CERo Therapeutics Holdings, Inc.
Phase 1
18
California, Colorado, Tennessee, Texas, Washington
2025-04-07
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
DrugsBBO-10203·MFOLFIRINOX·MFOLFOX6·Cetuximab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
Context Therapeutics Inc.
Phase 1
70
Colorado, Illinois, Michigan, New Jersey, Pennsylvania, Tennessee, Texas
2025-03-31
Active, closed
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812Solid Tumors
DrugsGEMNabP·MFOLFIRINOX·Cetuximab
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects
NCT06843577Elevated Blood Pressure, Hypertension
Zona Health, Inc
Not applicable
160
California, Florida, Illinois, Kentucky, Pennsylvania, Tennessee, Texas
2025-03-27
Recruiting
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
NCT06764771Advanced Malignant Tumors
DrugsAdagrasib·Erbitux·Opdivo·Cetuximab
Bristol-Myers Squibb
Phase 1
437
New Jersey, Pennsylvania, Tennessee, Texas
2025-03-25
Recruiting
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT06827613Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
DrugsSTAR0602·Sacituzumab Govitecan
Marengo Therapeutics, Inc.
Phase 1/2
50
California, Massachusetts, Ohio, Tennessee, Texas
2025-03-24
Recruiting
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
NCT06843317RSV Infection
DrugArexvy
Clover Biopharmaceuticals USA, LLC
Phase 1
160
Arizona, Florida, Kentucky, Missouri, Tennessee
2025-03-21
Recruiting
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
NCT06799065Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128MTAP-deleted Solid Tumors
Bayer
Phase 1/2
450
Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee
2025-03-21
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635Breast Neoplasms, Breast Cancer
DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Recruiting
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
NCT06874335Solid Tumor
DrugCemiplimab
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Recruiting
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
NCT06703489Ventricular Tachycardia (VT)
Medtronic Cardiac Ablation Solutions
Not applicable
60
Massachusetts, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-03-18
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Active, closed
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT06833008Advanced Solid Tumor
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT06950034Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
Solu Therapeutics, Inc
Phase 1
105
California, Florida, Massachusetts, Minnesota, Oregon, Tennessee, Texas
2025-03-13
Recruiting
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Iovance Biotherapeutics, Inc.
Phase 1/2
42
Colorado, North Carolina, Tennessee
2025-03-11
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
DrugsCisplatin/Carboplatin·MFOLFIRINOX·MFOLFOX6·Midazolam
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
California, Iowa, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas
2025-03-05
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Active, closed
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231Multiple System Atrophy
Dasher Neuroscience Inc.
Phase 2
75
California, Massachusetts, Minnesota, New York, Tennessee, Texas
2025-03-03
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Michigan, New York, Tennessee, Texas, Washington
2025-02-28
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
SNV4818 in Participants With Advanced Solid Tumors
NCT06736704Advanced Solid Tumors
DrugsPalbociclib·Fulvestrant
Pikavation Therapeutics, Inc.
Phase 1/2
320
California, Massachusetts, Pennsylvania, Tennessee, Texas
2025-02-20
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
DrugsDomvanalimab·Zimberelimab·Paclitaxel·Carboplatin
Gilead Sciences
Phase 2
39
Missouri, Tennessee, Texas
2025-02-18
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
DrugSevabertinib
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Hawaii, Kentucky, Missouri, South Carolina, Tennessee, Texas
2025-02-10
Recruiting
Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples
NCT06803927Barrett Esophagus
Cyted Health Inc
Observational
700
Tennessee
2025-02-05
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Recruiting
Clinical Outcome Measure at Stryker Spine
NCT06226272Degenerative Disc Disease, Degenerative Scoliosis
VB Spine, LLC
Observational
5,222
Florida, Maine, Michigan, Ohio, Tennessee, Texas
2025-01-28
Recruiting
Validity of Viome's Oral/throat Cancer Test
NCT06174428Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
Viome
Observational
1,000
Missouri, Tennessee
2025-01-27
Active, closed
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
Cogent Biosciences, Inc.
Phase 1/2
110
California, Florida, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania, Tennessee
2025-01-22
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360SLE, SLE (Systemic Lupus)
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
24
Arizona, Florida, Iowa, New York, Tennessee, Texas, Utah
2025-01-21
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
NCT06632951Urothelial Carcinoma
DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine
AbbVie
Phase 2
150
Arkansas, California, Connecticut, Delaware, Florida, New York, Ohio, Tennessee
2025-01-20
Recruiting
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
NCT06517888Vestibular Schwannoma
Akouos, Inc.
Phase 1/2
27
Maryland, Minnesota, Tennessee, Texas
2025-01-17
Active, closed
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
NCT06715124Advanced Solid Tumors
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Michigan, New York, Pennsylvania, Tennessee
2025-01-14
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
DrugBGB-58067
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
NCT06759649Neoplasm, Cancer, Malignant Tumors
DrugZimberelimab
Compugen Ltd
Phase 1
200
Connecticut, Massachusetts, Michigan, Tennessee, Texas, Virginia
2025-01-07
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugR-DXd
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Recruiting
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
NCT05960929Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
ONY
Phase 3
220
Arizona, California, Florida, Hawaii, New Jersey, New York, Tennessee, Utah
2025-01-01
Active, closed
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509Solid Tumours
Boehringer Ingelheim
Phase 2
90
California, Connecticut, Florida, Missouri, Nebraska, New York, Tennessee, Texas
2024-12-30
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Active, closed
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
NCT06688058Healthy
DrugNonavalent HPV vaccine
Merck Sharp & Dohme LLC
Phase 1
72
Florida, Georgia, Missouri, Tennessee
2024-12-20
Recruiting
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
NCT06797336Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
240
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Active, closed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
NCT07667322Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 1
75
California, Florida, Georgia, Maryland, Tennessee
2024-12-17
Recruiting
Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884Eye Cancer, Primary Cancer
DrugBel-sar
Aura Biosciences
Phase 2
24
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Tennessee
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Connecticut, Florida, Georgia, Mississippi, New York, Ohio, Pennsylvania, Tennessee
2024-12-16
Active, closed
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
NCT06733441Lymphoma
DrugZeprumetostat
Treeline Biosciences, Inc.
Phase 1
50
California, Missouri, New York, Tennessee
2024-12-16
Recruiting
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Fresenius Kabi
Observational
40
California, Illinois, Massachusetts, Ohio, Oklahoma, Tennessee, Texas, Washington
2024-12-15
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
NCT06645886Hematologic Malignancies, Adult
DrugsKQB198·Dasatinib
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Recruiting
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
NCT04679844Degenerative Disc Disease, Spine Fusion, Back Pain
Kuros Biosurgery AG
Not applicable
60
California, Michigan, Missouri, Pennsylvania, Tennessee, Washington
2024-12-06
Recruiting
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
NCT06655324Healthy
Merck Sharp & Dohme LLC
Phase 1
250
California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee
2024-12-05
Recruiting
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
Recursion Pharmaceuticals Inc.
Phase 1/2
170
California, Ohio, Tennessee, Utah
2024-11-21
Active, closed
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329Non-Small Cell Lung Cancer
DrugsMarlotamig·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
120
California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee
2024-11-18
Recruiting
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06752681Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
Recruiting
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
NCT06644755Solid Tumors, Sarcoma
Daiichi Sankyo
Phase 1
150
Massachusetts, New York, Tennessee
2024-11-14
Active, closed
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
NCT06654895Sepsis, Septic Shock
Bluejay Diagnostics, Inc.
Observational
700
Florida, Massachusetts, North Carolina, Tennessee, Utah
2024-11-12
Recruiting
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
NCT06462729Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Locate Bio Pty Ltd
Phase 1/2
40
Indiana, North Carolina, Tennessee
2024-11-12
Active, closed
Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice
NCT06685133Lung Cancer, Lung; Nodule
Noah Medical
Observational
50
Tennessee, Virginia
2024-11-08
Recruiting
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
NCT06492733Chronic Total Occlusion of Artery of the Extremities
Versono Medical Ltd
Not applicable
65
Delaware, Florida, Iowa, Louisiana, Michigan, Tennessee
2024-11-05
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
NCT06656390Advanced Cancer, Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Colorado, Florida, Louisiana, Tennessee
2024-10-24
Active, closed
A Study of DM001 in Patients With Advanced Solid Tumors
NCT06475937Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1
128
Tennessee, Texas
2024-10-24
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117Solid Tumor, MET Alteration
Pierre Fabre Medicament
Phase 1/2
140
District of Columbia, Ohio, Tennessee
2024-10-22
Recruiting
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
NCT06430385Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
48
California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2024-10-21
By invitation
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
NCT06559176Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Prime Medicine, Inc.
Phase 1/2
12
California, Maryland, Tennessee
2024-10-17
Recruiting
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT06525636X-linked Hypophosphatemia
Kyowa Kirin Co., Ltd.
Phase 1/2
39
California, Connecticut, Indiana, Minnesota, Tennessee
2024-10-09
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
200
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Tennessee
2024-10-09
Recruiting
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
NCT06527872Lupus Nephritis
GlaxoSmithKline
Observational
300
Maryland, North Carolina, Ohio, Tennessee
2024-10-04
Recruiting
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
NCT06686472Allergic Conjunctivitis
DrugTL-925
Telios Pharma, Inc.
Phase 2
66
Tennessee
2024-10-03
Active, closed
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258Alzheimer's Disease
DrugsE2814·Lecanemab
Eisai Inc.
Phase 2
105
Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee
2024-09-30
Recruiting
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
NCT06512454Alpha1-Antitrypsin Deficiency
Takeda
Observational
500
Florida, South Carolina, Tennessee
2024-09-25
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament
Phase 1/2
171
Tennessee, Texas
2024-09-17
Recruiting
Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA
NCT06659055Healthy, Indicated for EOSedge Imaging
Alphatec Spine, Inc.
Not applicable
214
Arizona, California, Tennessee, Virginia
2024-09-11
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
DrugGlofitamab
Arvinas Inc.
Phase 1
329
Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas
2024-09-05
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
California, District of Columbia, Florida, Illinois, North Carolina, Pennsylvania, Tennessee, Utah
2024-09-03
Recruiting
First In Human Study of CX-801 in Advanced Solid Tumors
NCT06462794Solid Tumor, Adult
DrugsKeytruda·Pembrolizumab
CytomX Therapeutics
Phase 1
121
California, Colorado, Pennsylvania, Tennessee, Texas
2024-08-28
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
NCT06415487Locally Advanced Solid Tumor, Metastatic Solid Tumor
DrugsFludarabine·Cyclophosphamide·Pembrolizumab
Acepodia Biotech, Inc.
Phase 1
30
California, Colorado, Tennessee, Texas
2024-08-22
Active, closed
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
Ossium Health, Inc.
Phase 1/2
12
California, Florida, Georgia, Michigan, Oregon, Tennessee, Texas, Utah
2024-08-16
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Active, closed
A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma
NCT06615661Primary Open Angle Glaucoma (POAG)
Iantrek, Inc.
Observational
100
Florida, Georgia, New York, Tennessee
2024-08-14
Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819Solid Tumor
Sumitomo Pharma America, Inc.
Phase 1/2
120
California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington
2024-08-14
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
DrugOlaparib
MOMA Therapeutics
Phase 1
220
Arizona, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Tennessee
2024-08-13
Active, closed
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809Glioblastoma
DrugsPD-L1 t-haNK·Avastin·Bevacizumab
ImmunityBio, Inc.
Phase 2
34
California, Tennessee
2024-08-07
Recruiting
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric LTD
Not applicable
15
California, Michigan, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Washington
2024-08-05
Active, closed
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
NCT06565611Obesity
DrugTirzepatide
Palatin Technologies, Inc
Phase 2
108
Florida, Oklahoma, South Carolina, Tennessee
2024-08-05
Active, closed
Combined Treatment Sofwave and Pure Impact to Strength and Tone Muscles and Improve Lax Skin Appearance
NCT06724146Skin Lax and Muscle Strength
Sofwave Medical LTD
Not applicable
70
Tennessee
2024-08-05
Recruiting
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
NCT05733598Hepatocellular Carcinoma, Biliary Tract Cancer
DrugsRP2·Tecentriq·Avastin·Atezolizumab
Replimune, Inc.
Phase 2
60
California, Florida, Maryland, New York, Pennsylvania, Tennessee, Texas
2024-08-01
Active, closed
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
NCT06565650Dry Eye
Bausch & Lomb Incorporated
Phase 4
216
California, Florida, Georgia, Indiana, Missouri, North Carolina, Tennessee
2024-07-31
Active, closed
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
NCT06239480Microcystic Lymphatic Malformation
DrugQTORIN rapamycin anhydrous
Palvella Therapeutics, Inc.
Phase 3
51
California, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-31
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Colorado, Florida, Missouri, Ohio, Tennessee, Texas
2024-07-24
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Alabama, Arizona, California, Illinois, New York, Pennsylvania, Tennessee, Texas
2024-07-23
Recruiting
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06480552Advanced Solid Tumors
DrugsTEV-56278·Keytruda·Pembrolizumab
Teva Branded Pharmaceutical Products R&D LLC
Phase 1
240
California, Florida, Illinois, Michigan, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-22
Recruiting
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
Angiex, Inc.
Phase 1
80
California, Florida, Missouri, Tennessee, Texas, Virginia
2024-07-22
Recruiting
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
NCT06046495Non-Small Cell Lung Cancer
DrugAndamertinib
Avistone Biotechnology Co., Ltd.
Phase 1
81
California, Kentucky, Nebraska, New York, Tennessee, Washington
2024-07-08
Active, closed
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619Thyroid Eye Disease
DrugTeprotumumab
Amgen
Phase 3
89
Arizona, Illinois, Michigan, Nevada, New Jersey, Oregon, Pennsylvania, Tennessee
2024-07-05
Recruiting
HPC Offered for PRESERVE Expansion
NCT07145411Bone Marrow Transplant (BMT)
Ossium Health, Inc.
Observational
10
Alabama, Michigan, Ohio, Tennessee
2024-06-27
Recruiting
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
DrugsVenclyxto·Venclexta·Venetoclax
BlossomHill Therapeutics
Phase 1
170
California, Florida, Illinois, New York, Ohio, Tennessee, Texas, Washington
2024-06-19
Recruiting
Study of SGR-3515 In Participants With Advanced Solid Tumors.
NCT06463340Advanced Solid Tumor
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Active, closed
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200Retinitis Pigmentosa
Ocugen
Phase 3
140
Arizona, California, Florida, Pennsylvania, Tennessee, Texas, Wisconsin
2024-06-18
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
285
Colorado, Florida, Massachusetts, Tennessee, Texas
2024-06-12
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
DrugsBelrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 3
88
Florida, Hawaii, Kentucky, Nebraska, Tennessee, Texas, Washington
2024-06-10
Recruiting
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976Hypochondroplasia
QED Therapeutics, a BridgeBio company
Observational
150
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2024-06-05
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06507306Solid Tumor, Adult
DrugsKQB198·Tagrisso·Amivantamab·Osimertinib
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Arizona, California, Florida, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2024-05-24
Recruiting
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
NCT06055439Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
Chimeric Therapeutics
Phase 1/2
135
Georgia, Illinois, Pennsylvania, Tennessee
2024-05-15
Active, closed
The ACES Study for Aseptic Pleural Effusion
NCT06210685Pleural Effusion
Pleural Dynamics, Inc.
Not applicable
25
Florida, Maryland, North Carolina, Tennessee
2024-05-12
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Active, closed
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702MTAP-deleted Solid Tumors
DrugTNG462
Servier Bio-Innovation LLC
Phase 1/2
60
Florida, Indiana, Ohio, Tennessee, Texas
2024-04-29
Active, closed
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
NCT06325748AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
DrugFludarabine
Senti Biosciences
Phase 1
21
California, Colorado, Florida, Tennessee, Texas
2024-04-22
Active, closed
A Pilot Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive
NCT06095531Craniotomy
RevBio
Not applicable
20
Massachusetts, Tennessee
2024-04-18
Active, closed
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
NCT06155500Sickle Cell Disease
Novartis Pharmaceuticals
Phase 1
4
Illinois, New York, Tennessee
2024-04-16
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
California, Illinois, Minnesota, New York, Tennessee, Texas, Utah, Virginia
2024-04-10
Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
Nested Therapeutics, Inc
Phase 1
230
California, Colorado, Connecticut, Florida, New York, Pennsylvania, Tennessee, Texas
2024-04-09
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
California, Connecticut, Tennessee, Virginia
2024-04-03
Recruiting
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Active, closed
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT06079372Hypophosphatasia
DrugsAsfotase alfa·ALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
43
Connecticut, Maryland, Minnesota, Missouri, North Carolina, Tennessee
2024-04-02
Recruiting
First In Human Study of CX-2051 in Advanced Solid Tumors
NCT06265688Solid Tumor, Adult
DrugsAvastin·Bevacizumab
CytomX Therapeutics
Phase 1
160
Colorado, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia
2024-04-02
Recruiting
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
NCT05848284Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
VDyne, Inc.
Not applicable
30
California, Michigan, Minnesota, New York, Ohio, Oregon, South Carolina, Tennessee
2024-04-01
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
NCT06158854Immunoglobulin Light Chain (AL) Amyloidosis
DrugEtentamig
AbbVie
Phase 1/2
76
Florida, Massachusetts, Minnesota, New York, North Carolina, Oregon, Tennessee, Washington
2024-04-01
Active, closed
OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier
NCT06447844Nonterminal Premolar Needing Extraction
McGuire Institute
Not applicable
70
Colorado, Massachusetts, Michigan, Nebraska, Tennessee, Texas, Wisconsin
2024-03-28
Active, closed
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514Relapsing Multiple Sclerosis
TG Therapeutics, Inc.
Observational
16
California, Georgia, Massachusetts, North Carolina, Tennessee
2024-03-26
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
Phase 1
85
Florida, Georgia, Indiana, Massachusetts, New York, Tennessee, Washington
2024-03-19
Recruiting
Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19
NCT06311435Long COVID
MaxWell Clinic, PLC
Not applicable
224
Iowa, Tennessee
2024-03-15
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Rhythm Pharmaceuticals, Inc.
Phase 1/2
150
Alabama, Illinois, Massachusetts, Tennessee, Texas, Utah
2024-03-05
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Recruiting
SNV1521 in Participants With Advanced Solid Tumors
NCT06220864Advanced Solid Tumor
DrugsDB-1310·Abiraterone·Darolutamide
Synnovation Therapeutics, Inc.
Phase 1
400
Connecticut, Pennsylvania, Tennessee, Texas, Utah
2024-02-23
Recruiting
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT06234423Ovarian Cancer, Solid Tumor
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Recruiting
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals
Observational
40
California, Colorado, District of Columbia, North Carolina, Ohio, Tennessee, Texas
2024-02-06
Recruiting
QTX3034 in Patients With KRAS G12D Mutation
NCT06227377Solid Tumors
Quanta Therapeutics
Phase 1
250
California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee
2024-02-05
Recruiting
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
NCT05916313Glioma
DrugObrixtamig
Boehringer Ingelheim
Phase 1
20
California, Tennessee
2024-01-30
Active, closed
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596Metastatic Urothelial Cancer
DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin
BicycleTx Limited
Phase 2
375
Colorado, Florida, Kansas, Kentucky, Nebraska, New York, South Carolina, Tennessee
2024-01-24
Recruiting
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251Relapsed and/or Refractory Multiple Myeloma
DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, California, Colorado, Connecticut, Florida, Massachusetts, New York, Tennessee
2024-01-23
Active, closed
Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children
NCT06285812Otitis Media Acute
PhotoniCare, Inc.
Observational
700
District of Columbia, Florida, New York, Oregon, South Carolina, Tennessee
2024-01-10
Recruiting
Tympanoseal Clinical Study
NCT05849844Tympanic Membrane Perforation
Grace Medical, Inc.
Not applicable
45
Michigan, Tennessee
2024-01-05
Active, closed
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390Post-Bariatric Hypoglycemia
RECORDATI GROUP
Phase 2
93
California, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, New York, Tennessee
2024-01-04
Active, closed
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
124
Indiana, New York, North Carolina, Ohio, Tennessee
2024-01-03
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Colorado, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2023-12-20
Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
DrugREM-422
Remix Therapeutics
Phase 1/2
125
California, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-12-20
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Michigan, Tennessee
2023-12-14
Recruiting
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074Advanced Solid Malignancies
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Active, closed
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
NCT06496568PIK3CA-Mutated Cancers
DrugsInavolisib·Atezolizumab
Hoffmann-La Roche
Phase 1
30
Tennessee
2023-12-11
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib
AstraZeneca
Phase 1/2
564
Missouri, Rhode Island, Tennessee, Texas
2023-12-05
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
DrugsTecentriq·Atezolizumab
Genentech, Inc.
Phase 1
65
Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee
2023-11-27
By invitation
Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder
NCT06283498Overactive Bladder Syndrome
InMode MD Ltd.
Not applicable
32
California, Tennessee
2023-11-10
Active, closed
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
NCT06079164Relapsed/Refractory Large B-cell Lymphoma
DrugsKITE-197·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 1
21
Florida, Illinois, Tennessee, Texas, Washington
2023-11-09
Recruiting
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT06075810Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
MBQ Pharma
Phase 1
48
California, Florida, Tennessee
2023-11-09
Recruiting
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050Advanced Solid Tumor, Metastatic Solid Tumor
DrugPembrolizumab
Jazz Pharmaceuticals
Phase 1
177
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2023-11-07
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
DrugsFOLFIRI Protocol·Zirabev·Mvasi·Regorafenib
Neonc Technologies, Inc.
Phase 1/2
134
California, Florida, Massachusetts, Tennessee, Texas, Washington
2023-11-01
Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
Phase 1
200
California, Florida, Georgia, Illinois, Massachusetts, New York, North Carolina, Tennessee
2023-11-01
Recruiting
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
NCT05977751Contraception
Femasys Inc.
Not applicable
573
Arizona, California, Georgia, Idaho, New York, Ohio, Tennessee, Utah
2023-10-31
Recruiting
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva
Stratpharma AG
Not applicable
2,000
Alabama, California, Florida, Georgia, Nevada, North Carolina, South Carolina, Tennessee
2023-10-30
Active, closed
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
NCT05657301Age-Related Macular Degeneration
DrugKH631
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
25
Arizona, Illinois, Massachusetts, Nevada, New Jersey, Tennessee, Texas
2023-10-16
Active, closed
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
NCT06082960Solid Tumors
DrugZimberelimab
Gilead Sciences
Phase 1
45
Connecticut, Tennessee, Texas
2023-10-09
Recruiting
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT05941507Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2
300
California, Massachusetts, Michigan, Tennessee, Texas
2023-10-05
Active, closed
GDNF Gene Therapy for Multiple System Atrophy
NCT04680065Multiple System Atrophy
DrugAAV2-GDNF gene therapy
Brain Neurotherapy Bio, Inc.
Phase 1
9
California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee
2023-10-03
Active, closed
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826Advanced Solid Tumor, Colorectal Cancer
TORL Biotherapeutics, LLC
Phase 1
70
California, Colorado, Indiana, Missouri, Tennessee, Texas
2023-09-29
Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament
Phase 1/2
345
California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia
2023-09-26
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Active, closed
Treatment of PAF With the Synaptic System
NCT05905835Paroxysmal Atrial Fibrillation
Synaptic Medical Corporation
Not applicable
128
Arizona, Arkansas, California, Missouri, New York, Tennessee, Texas, Virginia
2023-09-20
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Eli Lilly and Company
Phase 3
48
California, Iowa, Massachusetts, Ohio, Pennsylvania, Tennessee
2023-09-15
Recruiting
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.
Phase 1
165
California, Massachusetts, Tennessee, Texas
2023-09-14
Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Vincerx Pharma, Inc.
Phase 1
36
Alabama, Ohio, Tennessee, Texas, Washington
2023-09-13
Active, closed
Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea
NCT06008626Obstructive Sleep Apnea of Adult
Cryosa, Inc.
Not applicable
25
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Texas
2023-09-12
Active, closed
Perform® Humeral System - Fracture Study (PFX)
NCT05773352Traumatic Arthropathy of Shoulder, Fracture Humerus, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains
Stryker Trauma and Extremities
Observational
118
Arizona, Arkansas, California, Florida, Illinois, Missouri, Tennessee, Texas
2023-08-31
Recruiting
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
AviadoBio Ltd
Phase 1/2
18
Ohio, Tennessee, Texas
2023-08-30
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DrugsDB-1310·Osimertinib·Trastuzumab·Capecitabine
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Alabama, California, Massachusetts, Nevada, New Jersey, New York, Ohio, Tennessee
2023-07-31
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
NCT05954312Advanced Solid Tumors
DrugsDocetaxel·Paclitaxel·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 1
290
Florida, Minnesota, Tennessee, Texas, Virginia
2023-07-28
Recruiting
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
NCT05886920Advanced Solid Tumors With MAPK Pathway Mutations
DrugD3S-001
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Michigan, New York, Tennessee, Texas
2023-07-10
Active, closed
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 2
160
Arizona, California, Florida, Michigan, Minnesota, New York, Pennsylvania, Tennessee
2023-07-03
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
DrugOlaparib
Artios Pharma Ltd
Phase 1/2
181
Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
2023-06-30
Active, closed
Myopia Control Spectacle Lens Cessation Study
NCT05893979Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
90
California, Florida, Kansas, Missouri, New York, Tennessee, Texas, Utah
2023-06-23
Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc
Phase 1
60
Colorado, Florida, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington
2023-06-20
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Dexamethasone
GlaxoSmithKline
Phase 1/2
123
Arizona, California, Florida, Massachusetts, Michigan, North Carolina, Ohio, Tennessee
2023-06-14
Active, closed
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
DrugsKeytruda·Pembrolizumab
Tango Therapeutics, Inc.
Phase 1/2
126
California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-06-12
Recruiting
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
NCT05948865Cancer, Cancer, Lung
DrugSYS6010
Conjupro Biotherapeutics, Inc.
Phase 1
132
California, Colorado, Florida, New Hampshire, Pennsylvania, Tennessee, Texas, Virginia
2023-06-06
Recruiting
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
NCT05930210Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Energenesis Biomedical Co., Ltd.
Phase 3
230
Florida, Georgia, Tennessee, Texas, Utah, Virginia
2023-05-30
Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831Locally Advanced Solid Tumor
DrugsTNG462·Keytruda·Pembrolizumab
Tango Therapeutics, Inc.
Phase 1/2
225
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New York, Tennessee
2023-05-26
Recruiting
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
NCT05907980Solid Tumor
DrugsAtezolizumab·Pembrolizumab
Chugai Pharmaceutical
Phase 1
209
Pennsylvania, Rhode Island, Tennessee, Texas, Virginia
2023-05-24
Active, closed
An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer
NCT05712473Prostate Cancer
Lantheus Medical Imaging
Observational
500
Alabama, Arkansas, California, Michigan, Missouri, Nebraska, Pennsylvania, Tennessee
2023-05-22
By invitation
G7 Freedom Constrained Vivacit-E Liners
NCT05587244Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures
Zimmer Biomet
Not applicable
202
Alabama, California, Florida, New Jersey, Ohio, Tennessee, Texas, Utah
2023-05-08
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York, Tennessee
2023-05-08
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda
Hoffmann-La Roche
Phase 2
199
Alabama, California, Georgia, Maryland, Tennessee, Texas
2023-04-21
Active, closed
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Legend Biotech USA Inc
Phase 1
56
Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington
2023-04-18
Recruiting
Pounce™ Thrombectomy System Retrospective Registry
NCT05868161Peripheral Arterial Disease, Acute Limb Ischemia
SurModics, Inc.
Observational
500
Illinois, Indiana, Louisiana, Minnesota, Ohio, South Carolina, South Dakota, Tennessee
2023-04-18
Active, closed
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
NCT05737784SCN2A-DEE, Epilepsy
Praxis Precision Medicines
Phase 1/2
60
Tennessee
2023-04-13
Active, closed
A Rollover Study of CC-122
NCT05688475Non-Hodgkin Lymphoma
DrugDexamethasone
Bristol-Myers Squibb
Phase 1
12
New York, Tennessee, Wisconsin
2023-04-11
Active, closed
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562Neoplasms, Rectal
DrugDostarlimab
GlaxoSmithKline
Phase 2
154
California, New Mexico, New York, Pennsylvania, Tennessee, Texas, Virginia
2023-04-03
Recruiting
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
NCT05776069Von Willebrand Diseases
DrugVGA039
Vega Therapeutics, Inc
Phase 1/2
116
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Texas, Washington
2023-03-16
Active, closed
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881Respiratory Syncytial Virus, Human Metapneumovirus
DrugsMRNA-1345·MRNA-1365·Nimenrix
ModernaTX, Inc.
Phase 1
186
California, District of Columbia, Illinois, Louisiana, North Carolina, Rhode Island, South Carolina, Tennessee
2023-02-15
Recruiting
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
NCT05683418HR+/HER2-negative Breast Cancer
DrugsRibociclib·Palbociclib·Fulvestrant
Totus Medicines
Phase 1
241
Illinois, Massachusetts, Nevada, Pennsylvania, Tennessee, Texas, Virginia
2023-02-15
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
42
California, Colorado, District of Columbia, Ohio, Pennsylvania, Tennessee, Washington, Wisconsin
2023-01-19
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
DrugsElacestrant·Exemestane·Everolimus·Abemaciclib
Ellipses Pharma
Phase 1/2
95
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia
2023-01-11
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
DrugSTAR0602
Marengo Therapeutics, Inc.
Phase 1/2
366
California, Florida, Kansas, Maryland, Massachusetts, Michigan, Ohio, Tennessee
2023-01-04
Active, closed
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532Breast Cancer
Accutar Biotechnology Inc
Phase 1
100
Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington
2022-12-29
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
California, Florida, Kentucky, Maryland, New York, North Carolina, Pennsylvania, Tennessee
2022-12-28
Active, closed
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
NCT05876780Limb Girdle Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 1
6
Ohio, Tennessee
2022-12-19
Active, closed
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
DrugsCHS-114·Toripalimab
Coherus Oncology, Inc.
Phase 1
87
California, Georgia, Kentucky, Maryland, Michigan, Missouri, Ohio, Tennessee
2022-12-15
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
California, Georgia, Illinois, Missouri, Nevada, New Jersey, New York, Tennessee
2022-11-25
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 1/2
310
Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington
2022-11-22
Active, closed
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT05394116Fibrodysplasia Ossificans Progressiva
DrugGaretosmab
Regeneron Pharmaceuticals
Phase 3
63
California, Tennessee
2022-11-21
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Massachusetts, New York, Pennsylvania, Tennessee
2022-10-26
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
DrugsTecentriq·Atezolizumab·Keytruda·Pembrolizumab
Genentech, Inc.
Phase 1
165
California, Colorado, Florida, Georgia, Massachusetts, Missouri, New Jersey, Tennessee
2022-10-20
Active, closed
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
NCT05535244Multiple Myeloma
DrugsCevostamab·Tocilizumab
Hoffmann-La Roche
Phase 1/2
90
Colorado, Florida, Maryland, Massachusetts, Minnesota, New York, Tennessee, Utah
2022-10-17
Active, closed
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378Lung Cancer, Non-Small Cell
DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 2
351
Florida, New Mexico, Tennessee, West Virginia
2022-10-14
Active, closed
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma
Jazz Pharmaceuticals
Phase 1
98
California, Colorado, Florida, Illinois, New York, Oklahoma, Pennsylvania, Tennessee
2022-10-10
Recruiting
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
NCT05187832Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC
Phase 1
61
Tennessee
2022-10-05
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891Cancer
EMD Serono Research & Development Institute, Inc.
Observational
700
Florida, Ohio, Tennessee
2022-10-04
Active, closed
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357Non-hodgkin Lymphoma
DrugEpcoritamab
Genmab
Phase 1
17
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2022-10-04
Active, closed
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms
DrugBel-sar
Aura Biosciences
Phase 1
55
Arkansas, California, Colorado, New York, Pennsylvania, South Carolina, Tennessee, Texas
2022-09-26
Active, closed
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093Relapsed/Refractory Follicular Lymphoma
DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine
Kite, A Gilead Company
Phase 3
231
California, Florida, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania, Tennessee
2022-09-22
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Arkansas, California, Florida, Maryland, Massachusetts, New York, Tennessee, Texas
2022-09-19
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
DrugEnpatoran
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
California, Florida, Indiana, Michigan, Minnesota, Ohio, Tennessee
2022-09-16
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
DrugsElacestrant·Abemaciclib
Stemline Therapeutics, Inc.
Phase 1/2
73
California, Illinois, Massachusetts, Michigan, Ohio, Oregon, Tennessee, Texas
2022-08-31
Recruiting
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
NCT05523947HER2-Positive Solid Tumor
Yuhan Corporation
Phase 1/2
147
Massachusetts, Tennessee
2022-08-26
Recruiting
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT05455619HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
SynDevRx, Inc.
Phase 1/2
52
California, Florida, Illinois, Michigan, Ohio, Pennsylvania, Tennessee, Texas
2022-08-26
Recruiting
A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT05234567Hypophosphatasia
DrugAsfotase alfa
Alexion Pharmaceuticals, Inc.
Observational
30
Connecticut, Illinois, Massachusetts, Missouri, New York, Ohio, Pennsylvania, Tennessee
2022-08-25
Active, closed
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
DrugJNJ-80948543
Janssen Research & Development, LLC
Phase 1
167
California, New York, Tennessee, Texas, Washington
2022-08-18
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
DrugsCeralasertib·Durvalumab
AstraZeneca
Phase 2
194
California, Florida, Maryland, Tennessee
2022-08-11
Recruiting
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
NCT05431270Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
DrugsNab-paclitaxel·Pemetrexed·Tislelizumab·Docetaxel
Phanes Therapeutics
Phase 1/2
40
North Carolina, Oklahoma, Tennessee, Texas, Virginia
2022-08-11
Active, closed
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
NCT05198323Acute Ischemic Stroke
Lumosa Therapeutics Co., Ltd.
Phase 2
66
Tennessee
2022-08-11
Active, closed
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080Herpes Zoster
GlaxoSmithKline
Phase 3
3,038
Arizona, Maryland, North Carolina, Pennsylvania, Tennessee, Texas, Utah
2022-08-10
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
341
Florida, Hawaii, New Jersey, New York, Tennessee
2022-08-03
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
California, Colorado, Florida, Michigan, Tennessee, Texas
2022-08-03
Recruiting
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn
DrugExa-cel
Vertex Pharmaceuticals Incorporated
Phase 3
26
New York, North Carolina, Tennessee
2022-08-02
Rows per page Showing 1–500 of 670
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/tennessee

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 670 of those studies with a site in Tennessee.

How many clinical trials are recruiting in Tennessee?

371 of the 670 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 24 have not yet opened recruitment, 252 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tennessee), 670 studies
PhaseStudiesRecruitingShare
Phase 120712330.9%
Phase 1/21359620.1%
Phase 21014215.1%
Phase 3853512.7%
Not applicable64359.6%
Observational61319.1%
Phase 2/31051.5%
Phase 4741%

Most active sponsors

Lead sponsors with the most studies (Tennessee)
Lead sponsorStudiesRecruiting
AstraZeneca278
Novartis Pharmaceuticals167
Hoffmann-La Roche154
Merck Sharp & Dohme LLC1412
AbbVie129
GlaxoSmithKline127
Janssen Research & Development, LLC115
Pfizer116
Amgen95
Genentech, Inc.93
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.